Issue: The VP of R&D of a client company had information that a particular subset of the insomnia market was underserved by current available therapies. He wished to verify this information and identify promising insomnia therapies facing patent expiry which might benefit from a rapid release formulation.
Nerac Analyst Approach: Nerac Analysts assessed the potential market for this rapid release insomnia therapy from the published literature and identified the few companies with products currently in development. A careful review of the patent literature identified assignees with IP disclosing both insomnia treatments and rapid release formulations. Careful analysis and comparison of the products in development in terms of pharmacokinetics and pharmacodynamics delineated the available market opportunities. A very promising marketed compound was identified with 2012 patent expiry and was highlighted as an excellent reformulation opportunity.
Client Benefit: The client obtained third-party corroboration of his information as well as a careful assessment of the market and identification of an excellent reformulation opportunity with which to move forward.
Nerac Analyst Approach: Nerac Analysts assessed the potential market for this rapid release insomnia therapy from the published literature and identified the few companies with products currently in development. A careful review of the patent literature identified assignees with IP disclosing both insomnia treatments and rapid release formulations. Careful analysis and comparison of the products in development in terms of pharmacokinetics and pharmacodynamics delineated the available market opportunities. A very promising marketed compound was identified with 2012 patent expiry and was highlighted as an excellent reformulation opportunity.
Client Benefit: The client obtained third-party corroboration of his information as well as a careful assessment of the market and identification of an excellent reformulation opportunity with which to move forward.
